Autres langues Annexin Pharmaceuticals AB

Actions

ANNX

SE0009664154

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:59 16/07/2024			Varia. 5j.	Varia. 1 janv.
0,75 ^SEK	-6,25 %		+22,95 %	+188,46 %

23/05	Annexin Pharmaceuticals AB (Publ) élit Mikael Lonn comme nouveau membre ordinaire du conseil d'administration	CI
30/04	Annexin Pharmaceuticals AB (Publ) annonce que l'étude de phase II a été entièrement recrutée avec des signaux positifs	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioStock: Annexin comments on acquisition and focus on ANXV in ophthalmology	28/06
Annexin’s rights issue 100 percent subscribed and resolution of directed issue to guarantors	30/05
Annexin celebrates 10 years and the largest owner takes a seat on the board	23/05
Annexin Pharmaceuticals AB Elects Mikael Lönn as New Ordinary Member of the Board of Directors	23/05
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	14/05
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	07/05
BioStock: Annexin's phase II study fully recruited with positive signals	30/04
Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	30/04
Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns	25/04
Annexin Pharmaceuticals AB Announces Updates on Last Patient is Treated with the Investigational New Drug ANXV in the Phase 2A Study	25/04
BioStock: Annexin towards completion of phase II study and share issue	18/04
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	12/04
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	28/03
BioStock: Strong start for Annexin in 2024	14/02
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09/02
Update on Annexin´s RVO study confirms promising signals of effect	08/02
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	08/02
Annexin presents at Redeye’s Fight Cancer event on January 24	18/01
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	18/12
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	30/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Annexin Pharmaceuticals AB

Actions

ANNX

SE0009664154

Autres langues

Filtres